| Title |
Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology
|
|---|---|
| Published in |
Journal of Neuro-Oncology, December 2017
|
| DOI | 10.1007/s11060-017-2708-1 |
| Pubmed ID | |
| Authors |
Joseph R. Linzey, Bernard L. Marini, Amy Pasternak, Cory Smith, Zac Miklja, Lili Zhao, Chandan Kumar-Sinha, Alyssa Paul, Nicholas Harris, Patricia L. Robertson, Lindsey M. Hoffman, Arul Chinnaiyan, Rajen Mody, Carl Koschmann |
| Abstract |
The number of targeted therapies utilized in precision medicine are rapidly increasing. Neuro-oncology offers a unique challenge due to the varying blood brain barrier (BBB) penetration of each agent. Neuro-oncologists face a difficult task weighing the growing number of potential targeted therapies and their likelihood of BBB penetration. We developed the CNS TAP Working Group and performed an extensive literature review for the evidence-based creation of the CNS TAP tool, which was retrospectively validated by analyzing brain tumor patients who underwent therapy targeted based on genomic results from an academic sequencing study (MiOncoseq, n = 17) or private molecular profiling (Foundation One, n = 7). The CNS TAP tool scores relevant targeted agents by applying multiple variables (i.e., pre-clinical data, clinical data, BBB permeability) to patient specific genomic information and clinical trial availability. In the Michigan cohort, the CNS TAP tool predicted the selected agent 85.7% of the time. The CNS TAP tool predicted the agent independently selected by pediatric neuro-oncologists in the Colorado cohort 50% of the time. Patients with recurrent brain tumors treated with agents predicted by the CNS TAP tool demonstrated a median progression-free survival of 4 months and four patients with recurrent high-grade glioma maintained ongoing partial responses of at least 6 months. The CNS TAP tool is a formalized algorithm to assist clinicians select the optimal targeted therapy for neuro-oncology patients. The CNS TAP tool has relatively high concordance with selected therapies and clinical outcomes in patients receiving targeted therapy in this heterogeneous retrospective cohort were promising. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 17% |
| United States | 1 | 17% |
| Unknown | 4 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 83% |
| Science communicators (journalists, bloggers, editors) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 36 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 19% |
| Student > Bachelor | 5 | 14% |
| Student > Ph. D. Student | 3 | 8% |
| Student > Master | 2 | 6% |
| Professor > Associate Professor | 2 | 6% |
| Other | 2 | 6% |
| Unknown | 15 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 25% |
| Neuroscience | 3 | 8% |
| Economics, Econometrics and Finance | 2 | 6% |
| Social Sciences | 2 | 6% |
| Psychology | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 17 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 April 2021.
All research outputs
#2,594,014
of 23,011,300 outputs
Outputs from Journal of Neuro-Oncology
#177
of 2,987 outputs
Outputs of similar age
#59,605
of 439,142 outputs
Outputs of similar age from Journal of Neuro-Oncology
#7
of 110 outputs
Altmetric has tracked 23,011,300 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,987 research outputs from this source. They receive a mean Attention Score of 4.2. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 439,142 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 110 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.